Tempus, a Chicago-based health IT technology company focused on collecting and integrating molecular and clinical data has announced a collaboration with Sanford Health to identify targeted therapies and clinical trials for breast cancer patients. Founded in 2015, Tempus continues to expand its network of partners and is currently working with leading academic medical centers, NCI designated cancer centers, hospital networks and community oncologists across the United States. As part of the
Read More
Tempus
Tempus Raises $70M to Expand Personalized Cancer Care Platform
Tempus, a technology company focused on helping doctors personalize cancer care by collecting and analyzing large volumes of molecular and clinical data, today announced it has raised $70 million in Series C funding. The Series C round was co-led by New Enterprise Associates (NEA) and Revolution Growth. This latest round brings the two-year-old company’s total funding to $130M.Cancer isn't only about where it grows. It's about how it grows. Genetic alterations drive cancer growth. Some
Read More
Tempus, Cleveland Clinic Collaborate on Personalized Cancer Medicine Initiative
Tempus, a technology company focused on helping doctors personalize cancer care by collecting and analyzing large volumes of molecular and clinical data, and Cleveland Clinic Taussig Cancer Institute will collaborate on a precision medicine initiative aimed at improving outcomes for patients diagnosed with cancer.As part of the research collaboration spanning multiple cancer subtypes, Tempus will provide molecular sequencing and analysis for patients enrolled in a precision oncology clinical
Read More
University of California Davis, Tempus Partner on Personalized Cancer Initiative
University of California Davis Comprehensive Cancer Center is collaborating with technology company Tempus on a precision medicine partnership. The new collaboration will focus on advancing clinical care with Next Generation Sequencing analysis for patients diagnosed with hematological malignancies and pancreatic cancer.Collaboration DetailsTempus will perform molecular sequencing and analysis for a group of patients at UC Davis Comprehensive Cancer Center. Utilizing machine learning and
Read More
University of California San Diego, Tempus Partner on Personalized Medicine Initiative
Tempus, a technology company focused on helping doctors personalize cancer care by collecting, sorting and analyzing clinical and molecular data, will provide Moores Cancer Center at UC San Diego Health with molecular sequencing, analysis and decision support tools to enable further research on immune checkpoint inhibitors across cancer types. Tempus provides molecular sequencing and clinical analytic solutions to top academic centers, hospital systems, associations, and healthcare
Read More
University of Chicago Medicine, Tempus Partner on Personalized Pancreatic Cancer Project
Pancreatic cancer is the third leading cause of cancer-related death in the United States. It has a five-year survival rate of just nine percent. Lack of effective treatments and early detection methods contribute to this grim prognosis. Personalized approaches to match a patient’s genomic information to therapies have led to improvements in treatment of other cancer types. None of the genetic mutations commonly seen in pancreatic cancer, however, have “druggable” targets.That’s why the
Read More
University of Michigan, Tempus Partner on Personalized Breast Cancer Medicine Initiative
Breast cancer is the most common non-skin cancer and the second leading cause of cancer-related death in women. In 2017, it is estimated that more than 250,000 U.S. women will be diagnosed with new cases of invasive breast cancer. That’s why the University of Michigan Comprehensive Cancer Center has partnered with Tempus on a personalized cancer medicine initiative aimed providing most effective care for individuals diagnosed with breast cancer.As part of the initiative, Tempus will use
Read More
Northwestern, Tempus Expand Partnership to Accelerate Personalizing Care for Cancer Patients
The Robert H. Lurie Comprehensive Cancer Center of Northwestern University is expanding its partnership with Tempus aimed at personalizing care for cancer patients. Tempus provides molecular sequencing and clinical analytic solutions for top academic centers, hospital systems, associations, and healthcare providers.As part of the expanded collaboration, Tempus will provide molecular sequencing and analysis for patient derived xenograft (PDX) models and patient derived organoid models, which will
Read More
Penn Medicine’s Abramson Cancer Center Launches Initiative to Improve & Personalize BRCA Mutations
Cancer experts at the Basser Center for BRCA in the Abramson Cancer Center of the University of Pennsylvania have announced a new collaboration with Tempus to improve and personalize treatment for patients with heritable BRCA mutations. Tempus, a technology company focused on helping doctors personalize cancer treatment will analyze the molecular and clinical data of patients who were treated at the Basser Center and harbor a BRCA mutation using machine learning and advanced
Read More
